Table 4 Adverse events reported by patients receiving dupilumab (N = 74)
Adverse events | N (%) |
|---|---|
At least 1 adverse event (AE) | 25 (33.8) |
Asthenia | 6 (8.1) |
Arthralgia | 5 (6.8) |
Conjunctivitis | 4 (5.4) |
Injection-site reaction | 3 (4.1) |
Nausea | 3 (4.1) |
Abdominal pain | 2 (2.7) |
Headache | 2 (2.7) |
Diarrhea | 1 (1.4) |
Dizziness | 1 (1.4) |
Orofacial HSV reactivation | 1 (1.4) |
Weight gain | 1 (1.4) |
Any AE leading to discontinuation of study | 0 (0) |